Dr David Thomson
David Thomson qualified from Oxford University Medical School in 2004 with a First Class honours degree. During his postgraduate medical training he undertook a research Fellowship at the University of Manchester with attachment to the University of Pennsylvania, and was awarded a Doctor of Medicine (MD) higher research degree in 2015. He also has an interest in medical education and completed a Postgraduate Certificate in Medical Education with Distinction (Edge Hill University, 2014). Dr Thomson was appointed Consultant Clinical Oncologist at The Christie (2015) and Honorary Senior Lecturer at The University of Manchester, specialising in the treatment of head and neck cancer.
As the Clinical Director of the Greater Manchester Head and Neck Cancer Pathway Board, he is passionate about improving the survival outcomes and long-term quality of life for patients. Dr Thomson is actively involved in clinical research and is Chief Investigator for the UK phase 3 NIMRAD trial (assessing the benefit of hypoxia modification using nimorazole with radiotherapy for head and neck cancer), Chief Investigator for the UK phase 3 TORPEdO trial (assessing benefit of proton beam therapy to reduce side effects in the treatment of oropharyngeal cancer), and Principal Investigator for a number of NCRI portfolio studies. He is Proton Beam Therapy National Policy Lead and National Panel Member for Head and Neck Cancer. Dr Thomson is also the clinical lead for the implementation of electronic patient reported outcomes in head and neck cancer at The Christie.
Claire Goldrick is the pathway manager for the head and neck pathway board.